Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ligand Pharmaceuticals (LGNYZ) Enterprise Value (2016 - 2025)

Historic Enterprise Value for Ligand Pharmaceuticals (LGNYZ) over the last 16 years, with Q3 2025 value amounting to -$664.5 million.

  • Ligand Pharmaceuticals' Enterprise Value fell 20254.64% to -$664.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$664.5 million, marking a year-over-year decrease of 20254.64%. This contributed to the annual value of -$256.2 million for FY2024, which is 5041.19% down from last year.
  • Latest data reveals that Ligand Pharmaceuticals reported Enterprise Value of -$664.5 million as of Q3 2025, which was down 20254.64% from -$245.0 million recorded in Q2 2025.
  • Ligand Pharmaceuticals' Enterprise Value's 5-year high stood at -$121.4 million during Q3 2022, with a 5-year trough of -$664.5 million in Q3 2025.
  • Over the past 5 years, Ligand Pharmaceuticals' median Enterprise Value value was -$226.9 million (recorded in 2024), while the average stood at -$262.4 million.
  • Per our database at Business Quant, Ligand Pharmaceuticals' Enterprise Value soared by 6273.09% in 2021 and then plummeted by 20254.64% in 2025.
  • Ligand Pharmaceuticals' Enterprise Value (Quarter) stood at -$341.1 million in 2021, then surged by 37.89% to -$211.9 million in 2022, then increased by 19.62% to -$170.3 million in 2023, then plummeted by 50.41% to -$256.2 million in 2024, then plummeted by 159.41% to -$664.5 million in 2025.
  • Its Enterprise Value was -$664.5 million in Q3 2025, compared to -$245.0 million in Q2 2025 and -$208.9 million in Q1 2025.